ARTICLE Archives

Rethinking Solidarity in Health – A European Perspective

Health Systems Under Pressure in Europe

Across Europe, health systems face mounting pressures. Workforce shortages, uneven access, and entrenched inequalities leave many citizens underserved, and public trust in institutions is eroding. The pandemic briefly rekindled a sense of shared responsibility, yet shifting geopolitical tensions and economic priorities have since drawn attention away from collective well-being. This context raises a vital question: what does solidarity in health mean in Europe today? This context was highlighted at the European Health Forum Gastein (EHFG) 2025, where policymakers, civil society representatives, and health experts discussed the challenges and opportunities for solidarity in health across Europe.

Health is not merely a commodity; it is the foundation for social cohesion and long-term resilience. Investing in preventive care, mental health, and social support is not a trade-off with economic competitiveness — it is a prerequisite. In the European Union alone, premature deaths in 2022 accounted for 2.4 million lost work-years, highlighting the societal and economic consequences of insufficient early action. Across member states, access to care remains uneven, chronic diseases are on the rise, and innovations are not uniformly available, leaving vulnerable populations facing overlapping disadvantages.

The Role of Preventive Care and Mental Health

Solidarity in health demands action at every level. Primary and community care serve as the first line of defense, with multidisciplinary teams — including doctors, nurses, psychologists, and social workers — partnering with civil society organisations to reach underserved groups. Examples from Andalusia, Portugal, and Estonia’s e-consultation payment model show how coordinated, person-centred approaches build trust, improve access, and empower citizens. Prevention, early detection, and health literacy must complement innovation, ensuring no one is left behind. In the EU, the average diagnostic delay for asthma is 4.5 years, underlining the need for timely, equitable care.

Digital Health Innovation and Equity

Digital transformation presents both promise and challenge. AI, big data, and digital health tools can enhance early detection and patient monitoring. They also improve system efficiency. However, they risk amplifying bias and mistrust if governance is weak.. Europe’s task is to combine innovation with ethical oversight, embedding transparency, accountability, and accessibility into every design decision. Initiatives like the European Health Data Space (EHDS) aim to unify interoperability, research, and patient empowerment under one framework, giving citizens control over their health data while supporting innovation and equity.

Health systems also intersect with broader social and environmental challenges. Climate change, rising social inequalities, and ageing populations disproportionately affect vulnerable groups, while end-of-life care and rare diseases expose gaps in equity, research, and policy. Across Europe, collaborative solutions — from shared patient pathways to cross-border networks — are essential. Health contributes approximately 10% of EU GDP and 9% of employment, demonstrating its central role in both social and economic stability. Public funding, strategic investment in long-term care, and multi-sector collaboration strengthen resilience and uphold solidarity. Notably, €170 million has been allocated to the EU’s Strategic Research and Innovation Agenda on Health and Climate Change, ensuring vulnerable populations are included in solutions.

Examples of Person-Centred Care in the EU

Ultimately, solidarity in health is not merely about funding or policies; it is a commitment to fairness, inclusivity, and collective responsibility. From innovative care models like Karolinska University Hospital’s “hospital at home” programme to Estonia’s digital solutions, Europe has examples of what works when equity and person-centred design guide decisions. Rebuilding trust and strengthening solidarity requires transparency, engagement with civil society, and measures that demonstrate care in action.

Europe’s social contract in health can be renewed, balancing competitiveness with care. When investments, innovation, and policies are guided by solidarity, the continent can ensure that health becomes the common ground on which trust is restored — measured not in slogans or speeches, but in the well-being of every citizen.

Read the EHFG report here

Text/adaptation: Ifiyenia Anastasiou for Kapa3

Free and Reduced Transportation for People with Disabilities and Large Families – What Changes in 2025

The Greek state is implementing significant changes regarding transportation for people with disabilities and large families in 2025. The new regulations simplify procedures, expand rights, and make public transport more accessible for all eligible individuals.

People with Disabilities (PwD)
Who is eligible:
Eligible individuals include people with disabilities with a disability rate of 67% or higher, or those receiving disability benefits from OPEKA. Totally blind individuals and holders of a digital Disability Card marked with levels II or III are exempt from income limits.

What changes:

Residency criteria are removed.
The right to free or reduced transportation now extends to one accompanying person, if needed.
Using the Disability Card for OASA, OSETH, KTEL, and Thessaloniki Metro is now simple with electronic or personalized card validation, without additional documents.

Practical use:

Free travel on OASA, OSETH, urban KTEL, and the municipalities of Kos and Rhodes.
50% discount on intercity KTEL routes.
Thessaloniki Metro requires topping up the ThessCard with zero fare.
Accompanying persons can travel without separate validation when accompanying the eligible individual.

Large Families
Who is eligible:
Eligible individuals are large families and their members, according to existing legislation protecting large families.

What changes:

Travel with OASA, OSETH, and KTEL becomes more flexible.
Free or discounted tickets are supported depending on the policy of each transport service.

Practical use:

Simple procedure for issuing travel passes through Citizens’ Service Centers (KEP) and relevant regional authorities.
Tickets are valid for urban and intercity transport services.

These new regulations simplify the daily lives of people with disabilities and large families, reduce bureaucracy, and make access to all public transport easier.

See the Official Government Gazette (FEK) here

Gut Microbiota: A Hidden Ally in Cancer Treatment

Our gut is home to trillions of microorganisms, collectively called the gut microbiota, which play a crucial role in digestion, immunity, and overall health. Excitingly, research is revealing that these tiny residents can also influence the effectiveness of cancer treatments—from immunotherapy to chemotherapy and beyond. Understanding this connection opens new possibilities for more personalized and effective cancer care.

Boosting Immunotherapy through Gut Microbes

Innovative therapies like CAR-T cell therapy, immune checkpoint inhibitors (ICIs), oncolytic viruses (OVs), and CpG-oligonucleotide immunotherapy have transformed cancer treatment in recent years. Studies show that the composition of gut microbiota can affect how well patients respond to these therapies.

For instance, certain bacteria—such as Ruminococcus, Faecalibacterium, and Akkermansia—are linked to better CAR-T outcomes, while broad-spectrum antibiotics may reduce therapy effectiveness. Similarly, gut microbes can enhance responses to ICIs by stimulating immune cells that attack tumors. OVs, which work by killing cancer cells and activating the immune system, also benefit from a healthy gut microbiota. Even CpG-based therapies are more effective when gut microbes activate immune pathways.

In short, a balanced gut microbiota can help “turn cold tumors into hot tumors,” making them more responsive to modern immunotherapies.

Gut Microbes and Traditional Treatments

Gut microbiota also affects chemotherapy and radiotherapy. Some microbes can influence drug metabolism, improving efficacy or reducing side effects. For example, bacteria like Enterococcus hirae and Barnesiella intestinihominis enhance the response to cyclophosphamide, a common chemotherapy drug, by activating immune cells.

On the other hand, disruptions in gut microbiota—often caused by antibiotics or radiation—can increase treatment toxicity, leading to issues like intestinal inflammation or mucositis. Promising strategies like fecal microbiota transplantation (FMT) and certain probiotics have shown potential to restore gut balance, reduce side effects, and improve overall outcomes.

Complementary Approaches: TCM and Probiotics

Traditional medicine can also benefit from gut microbes. Traditional Chinese Medicine (TCM) compounds, when processed by gut bacteria, can transform into more potent anti-cancer agents. Certain TCM herbs and formulas can also promote beneficial bacteria while suppressing harmful ones.

Similarly, probiotics, prebiotics, and synbiotics—foods or supplements that nourish or contain helpful bacteria—can support cancer treatment by strengthening gut immunity, reducing inflammation, and enhancing drug effectiveness. For example, in combination with chemotherapy or immunotherapy, synbiotics have been shown to reduce treatment-related side effects while boosting therapeutic benefits.

Emerging Strategies: Engineering the Microbiota

Beyond diet and probiotics, scientists are developing targeted microbiota interventions to fight cancer more precisely. These include:

Engineered microbes, designed to deliver anti-cancer agents directly to tumors.
Phage therapy, using viruses that selectively kill harmful bacteria.
Nanomedicine and OMVs (outer membrane vesicles), which can deliver drugs or immune-stimulating molecules to tumors while sparing healthy microbes.

These cutting-edge approaches are still under study, but they demonstrate the incredible potential of harnessing gut microbes to improve therapy effectiveness and reduce toxicity.

Looking Ahead: Precision Medicine and Microbiota

The future of cancer treatment may increasingly involve personalized microbiota strategies. By analyzing an individual’s gut bacteria and metabolites, clinicians could tailor therapies to maximize efficacy and minimize side effects. Combining microbiota profiling with multi-omics analysis, AI, and big data could allow doctors to predict treatment response and guide interventions in a way that was unimaginable just a decade ago.

While challenges remain—including differences in individual microbiotas, safety considerations, and regulatory hurdles—the potential is enormous. Gut microbiota represents a promising frontier in precision oncology, offering hope for more effective, safer, and individualized cancer care.

Read the full article here

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

Sleep and Cancer: Understanding Insomnia and Nighttime Disorders

Sleep disturbances are common in people living with cancer, affecting physical health, emotional well-being, and quality of life. Insomnia—difficulty falling asleep, staying asleep, or obtaining restorative sleep—is one of the most frequent issues. It can occur at any stage of cancer and may be triggered or worsened by the cancer itself, treatments such as chemotherapy, medications, anxiety related to diagnosis, or lifestyle factors like caffeine, alcohol, or limited daytime activity.

Often, insomnia begins after a sudden change in life or medication. Over time, certain behaviors may make it chronic, such as sleeping with lights or TV on, napping during the day, or consuming caffeine or alcohol in the evening. Patients with coexisting conditions, such as anxiety or depression, may be particularly vulnerable.

Clinical approaches to insomnia
Evidence supports a multi-faceted strategy. Cognitive Behavioral Therapy for Insomnia (CBT-I) has been shown to reduce sleep complaints in cancer patients and may decrease reliance on hypnotic medications. CBT-I addresses maladaptive sleep behaviors and beliefs and can be delivered in-person or through digital programs, such as the FDA-cleared application Somryst.

Pharmacological treatment may be indicated for severe or persistent insomnia, typically as short-term therapy. Commonly prescribed medications include benzodiazepine receptor agonists (e.g., zolpidem, eszopiclone), low-dose doxepin, and orexin receptor antagonists. However, evidence in cancer patients remains limited, and medication should be closely monitored to avoid long-term dependence.

Parasomnias: nocturnal behavioral events
Some patients experience unusual behaviors during sleep, including sleepwalking, night terrors, or acting out dreams (REM sleep behavior disorder). These events may be influenced by treatment, medications, metabolic changes, or other medical conditions, and can sometimes be confused with seizures or delirium. Accurate documentation of the timing, frequency, behaviors, and memory of events is crucial for diagnosis. In cases where safety is at risk, or the events are atypical, video polysomnography may be recommended.

It is a fact that sleep affects multiple physiological processes, and disruptions can influence both quality of life and potentially cancer outcomes. A comprehensive, individualized approach—considering behavioral strategies, careful use of medication, and evaluation for other sleep disorders—is essential. Ongoing research is expanding our understanding of sleep’s role in cancer progression and patient resilience.

At Kapa3, we recognize the importance of sleep in supporting the overall well-being of people living with cancer, and we encourage patients to seek guidance on managing sleep disturbances as part of comprehensive care.

Read the full article here

Text/Adaptation: Ifiyenia Anastasiou for Kapa3

When Strength Emerges from Adversity

When Strength Emerges from Adversity
Understanding Post-Traumatic Growth in People Affected by Cancer

When we talk about the psychological state of a cancer patient, the words that usually come to mind are heavy ones: shock, pain, loss, depression. For many years, research focused mainly on the negative consequences of trauma, such as post-traumatic stress disorder (PTSD).

In recent decades, however, scientists and psychologists have started to recognize another, less familiar but equally important reality: out of pain, something positive can also emerge. Some people don’t just “bounce back” from adversity — they undergo profound change, discovering new meaning in life and strengthening their relationships. This process is called Post-Traumatic Growth (PTG).

What is Post-Traumatic Growth (PTG) in Cancer Survivors?

Post-Traumatic Growth (PTG) refers to the positive psychological changes that can emerge after facing traumatic experiences such as cancer. Instead of remaining “stuck” in the trauma, survivors may develop greater resilience, a renewed sense of purpose, and deeper connections with others.

Key Findings

Psychological Factors

Emotional Regulation: The ability to manage emotions is linked to higher PTG.
Sense of Purpose: Discovering or renewing life’s meaning strengthens growth.
Self-Esteem: A healthy self-image supports positive change.

Predictive Factors

Social Support: Strong relationships foster recovery and growth.
Spirituality: Personal beliefs can act as a protective factor.
Coping Strategies: Healthy ways of dealing with challenges (like positive reframing) promote PTG.

Helpful Interventions

Psychological Support: Therapies that focus on PTG show promising results.
Support Groups: Sharing experiences with others can enhance recovery.
Educational Programs: Learning tools for resilience empowers survivors.

At the end of the day, every cancer journey is unique — but for many, pain can also give rise to an unexpected new strength. PTG does not erase sorrow or struggle; it simply shows that alongside trauma, something meaningful can take root and carry life forward. And it is exactly this understanding of PTG that gives us yet another reason to stand by people with cancer through their difficult path — with respect, patience, and genuine presence.

Read the full article here